Feb 17 |
When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
|
Jan 10 |
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
|
Dec 14 |
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
|
Nov 15 |
Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript
|
Nov 15 |
Bio-Path GAAP EPS of -$0.32 beats by $0.02
|
Nov 15 |
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
|
Nov 15 |
Bio-Path Hldgs: Q3 Earnings Insights
|